Michael Murphylarkin

Michael Murphy-Larkin currently serves as a Manufacturing Specialist at Nucleus RadioPharma, where he plays a pivotal role in supporting the company's transition into its new clinical radiopharmaceutical manufacturing facility. His expertise is instrumental in ensuring the site’s GMP readiness, regulatory compliance, and robust documentation practices, which are critical for the successful production of innovative radiopharmaceutical therapies. Michael’s deep understanding of USP <825> guidelines, 21 CFR Parts 210 & 211, and quality assurance protocols underpins his contributions to facility startup activities, including equipment validation, process validation, and establishing quality control measures.

In his role, Michael is actively involved in overseeing the implementation of high-performance liquid chromatography (HPLC) and other pharmaceutical analysis techniques to ensure the purity, potency, and safety of radiopharmaceutical products such as [In-111]-FPI-1547. His background in organic chemistry and pharmaceutical sciences enables him to troubleshoot complex manufacturing challenges and optimize filtration and sterilization processes. Moreover, Michael’s leadership in cross-functional teams fosters a culture of compliance and continuous improvement, aligning operational practices with industry standards.

His key projects include supporting the validation of production processes, developing comprehensive documentation for regulatory submissions, and establishing quality assurance frameworks that uphold the highest standards of patient safety. With a keen eye for detail and a proactive approach, Michael Murphy-Larkin is dedicated to advancing radiopharmaceutical manufacturing excellence, ultimately contributing to the delivery of innovative diagnostic and therapeutic options in nuclear medicine.